CpG Motifs as Proinflammatory Factors Render Autochthonous Tumors Permissive for Infiltration and Destruction
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In a transgenic mouse model expressing SV40 T Ag (Tag) as a de novo tumor Ag, immune surveillance fails and islet cell carcinomas grow progressively. To develop an anticancer strategy that would be effective in eradicating solid, autochthonously growing tumors, we evaluated the effectiveness of immunostimulatory oligodeoxynucleotides (ODN) with cytosine-guanine-rich (CpG) motifs (CpG-ODN). In a classical vaccination protocol, Tag was administered with CpG-ODN as adjuvant. The antitumor vaccination, however, was only effective in a prophylactic setting, despite the successful activation of a Tag-specific CTL response in vivo. Histological examination demonstrated that even primed immune cells failed to infiltrate tumors once a malignant environment was established. To ensure that effector cells were not limiting, highly activated tumor Ag-specific T cells were transferred into tumor-bearing mice. However, this treatment also failed to result in tumor infiltration and rejection. Therefore, we further tested the efficacy of CpG-ODN as a proinflammatory agent in combination with the transfer of preactivated Tag-specific CD4+ and CD8+ T cells. Indeed, this combination therapy proved to be highly effective, because CpG-ODN rendered insulinomas permissive for massive infiltration and destruction. The opening of tumor tissue correlated with uptake of CpG-ODN by tissue-resident macrophages and a strong up-regulation of adhesion molecules such as ICAM and VCAM on blood vessel endothelia. These data demonstrate that systemic application of proinflammatory reagents drastically enhances extravasation of effector cells into tumor tissue, an observation that is of general importance for immunotherapy of solid tumors in a clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rabinowitz, S. S., & Gordon, S. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.827 · Cited by 233 · cited 7×
“However, the majority of CpG-ODN colocalized with FA/11 (Fig.”
BackgroundSelf-citation
Cited by
Klug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R. H., Timke, C., Umansky, L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.014 · Cited by 1,099
Self-citationLugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966
“Our studies have shown that radiation-induced damage can up-regulate VCAM-1 expression on tumor vessels, thus making them amenable to T cell migration, as has recently been shown for other types of inflammatory mediators (50).”
BackgroundCell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
Harjunpää, H., Llort Asens, M., Guenther, C., & Fagerholm, S. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01078 · Cited by 764
Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H. H., Rabie, T., Kaden, S., Gröne, H.-J., Hämmerling, G. J., et al. (2008) · Nature · doi:10.1038/nature06868 · Cited by 564
Self-citationGuiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Self-citationCarretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501
Self-citationDudley, A. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006536 · Cited by 424
“Indeed, the penetration and efficacy of primed T cells for tumor immunotherapy was enhanced when proinflammatory agents that up-regulated ICAM and VCAM in the vasculature were coadministered (Garbi et al. 2004).”
BackgroundSustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120944 · Cited by 419
Self-citationCD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
Kim, H.-J., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0216 · Cited by 380
Johansson-Percival, A., He, B., Li, Z.-J., Kjellén, A., Russell, K., Li, J., Larma, I., & Ganss, R. (2017) · Nature Immunology · doi:10.1038/ni.3836 · Cited by 331
Self-citationEngelhardt, J. J., Boldajipour, B., Beemiller, P., Pandurangi, P., Sorensen, C., Werb, Z., Egeblad, M., & Krummel, M. F. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.008 · Cited by 330
Müller-Hermelink, N., Braumüller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., Ghoreschi, K., Yazdi, A., Haubner, R., Sander, C. A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.001 · Cited by 302
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276
Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.05.001 · Cited by 159
Gene Therapy to Manipulate Effector T Cell Trafficking to Tumors for Immunotherapy
Gough, M., Crittenden, M., Thanarajasingam, U., Sanchez-Perez, L., Thompson, J., Jevremovic, D., & Vile, R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5766 · Cited by 60
“Both naive and activated effectors have demonstrated that they are unable to traffic to tumor sites expressing their specific Ag; however, delivery of proinflammatory factors that change the tumor microenvironment allows infiltration of activated T cells and tumor destruction (8).”
Background
Metadata
- Authors
- Garbi, N., Arnold, B., Gordon, S., Hämmerling, G. J., & Ganss, R.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-05
- Volume
- 172
- Issue
- 10
- Pages
- 5861-5869
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1626137214
- Cited by
- 127
- References
- 1
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.